Seguimiento de 3 años de pacientes con lesiones de bifurcación tratados con stents liberadores de sirolimus o everolimus: estudio de colaboración de SEAside y CORpal |
| |
Authors: | Manuel Pan Francesco Burzotta Carlo Trani Alfonso Medina Jose Suárez de Lezo Giampaolo Niccoli Miguel Romero Italo Porto Francisco Mazuelos Antonio Maria Leone Pedro Martín Valentina Coluccia Javier Suárez de Lezo Soledad Ojeda Filippo Crea |
| |
Institution: | 1. Servicio de Cardiología, Hospital Reina Sofía, Universidad de Córdoba (IMIBIC), Córdoba, España;2. Institute of Cardiology, Catholic University of the Sacred Heart, Roma, Italia;3. Servicio de Cardiología, Hospital Dr. Negrín, Universidad de Las Palmas, Las Palmas de Gran Canaria, España |
| |
Abstract: | Introduction and objectivesTo compare the 3-year incidence of major events in patients with bifurcation lesions treated with provisional sirolimus-eluting stents vs everolimus-eluting stents.MethodsA pooled analysis of 2 prospective randomized trials with similar methodology (SEAside and CORpal) was performed. In these trials, 443 patients with bifurcation lesions were randomly assigned to treatment with either sirolimus-eluting stents or everolimus-eluting stents. The clinical follow-up was extended up to 3 years to assess major adverse cardiovascular events (death or acute myocardial infarction or target vessel revascularization).ResultsAt 3 years, survival free of major adverse cardiovascular events was 93.2% vs 91.3% in the everolimus-eluting stent group vs the sirolimus-eluting stent group (P = .16). Exploratory land-mark analysis for late events (occurring after 12 months) showed significantly fewer major adverse cardiovascular events in the everolimus-eluting stent group: 1.4% vs 5.4% in the sirolimus-eluting stent group (P = .02).ConclusionsProvisional stenting with either sirolimus-eluting stents or everolimus-eluting stents in bifurcation lesions is associated with low rates of major adverse events at 3-years’ follow-up. The results of a subanalysis of events beyond 1 year, showing a lower event rate with everolimus-eluting stents than with sirolimus-eluting stents, suggest that studies exploring the long-term clinical benefit of the latest generation of drug-eluting stents are warranted.Full English text available from: www.revespcardiol.org/en |
| |
Keywords: | MACE eventos adversos cardiovasculares mayores RL rama lateral SLE stents liberadores de everolimus SLF stents liberadores de fá rmacos SLS stents liberadores de sirolimus VP vaso principal |
本文献已被 ScienceDirect 等数据库收录! |
|